Abingworth Overview
- Investor Type
-
Venture Capital
- Status
-
Active
- Professionals
-
16
- Investments
-
266
- Portfolio
-
30
- Exits
-
161
Abingworth General Information
Company Description
Founded in 1973, Abingworth is a venture capital firm based in London, United Kingdom. The firm prefers to invest in seed-stage, early-stage, growth-stage, and later-stage companies. The firm seeks to invest in healthcare, information technology, life science, and technology-based sectors in the United States and Europe.
Business Details
Website
www.abingworth.comYear Founded
Investor Status
Trade Association
Primary Investor Type
Other Investor Types
Corporate Office
- 38 Jermyn Street
- London SW1Y 6DN
- England, United Kingdom
Abingworth Investments & Acquisitions (266)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
|---|---|---|---|---|---|---|
| Glycomine | 16-Apr-2025 | Later Stage VC | Drug Discovery | Clinical Trials - Phase 2 | ||
| Atsena Therapeutics | 02-Apr-2025 | Drug Discovery | Clinical Trials - Phase 2 | |||
| AdvanCell | 03-Feb-2025 | Drug Discovery | Clinical Trials - Phase 1 | |||
| Timberlyne Therapeutics | 09-Jan-2025 | Drug Discovery | Clinical Trials - General | |||
| Ascend (Biotechnology) | 12-Nov-2024 | Biotechnology | Startup | |||
| Cytospire Therapeutics | 01-Oct-2024 | Biotechnology | Startup | |||
| Scorpion Therapeutics | 16-Jul-2024 | Drug Discovery | Generating Revenue | |||
| Myricx Bio | 08-Jul-2024 | Drug Discovery | Generating Revenue | |||
| Iambic | 18-Jun-2024 | Later Stage VC | Drug Discovery | Clinical Trials - Phase 1 | ||
| Teva Pharmaceutical Industries | 17-Apr-2024 | PIPE | Pharmaceuticals | Generating Revenue/Not Profitable |
Abingworth Exits (161)
| Company Name | Exit Date | Exit Type | Exit Size |
|---|---|---|---|
| Gynesonics | 02-Jan-2025 | Merger/Acquisition | |
| Vera Therapeutics | 30-Oct-2024 | ||
| Reneo Pharmaceuticals | 04-Oct-2024 | ||
| Escient Pharmaceuticals | 30-May-2024 | ||
| ReNeuron Group | 20-Mar-2024 | ||
| Pixium Vision | 31-Jan-2024 | ||
| Sierra Oncology | 01-Jul-2022 | ||
| HilleVax | 29-Apr-2022 | ||
| Vera Therapeutics | 10-Feb-2022 | Public Investment 2nd Offering | |
| Adaptate Biotherapeutics | 10-Jan-2022 | Merger/Acquisition |
Abingworth Fund Performance
| Fund Name | Vintage | Size | Dry Powder | DPI | RVPI | TVPI | IRR |
|---|
Abingworth Investments by Industry, Year, and Region
Investments by Industry
Investments by Year
Investments by Region
Abingworth Co-Investors (151)
| Name | With | Exits | Lead Partner | Series | Industry |
|---|---|---|---|---|---|
| Citadel Enterprise Americas | 3 |
|
|
||
| Novo Holdings |
|
|
|||
| OrbiMed |
|
|
|||
| Osage University Partners |
|
|
|||
| RiverVest Venture Partners |
|
|
Abingworth Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Abingworth Second Partner | London, United Kingdom | 2012 |
Abingworth FAQs
-
What is Abingworth?
Founded in 1973, Abingworth is a venture capital firm based in London, United Kingdom.
-
When was Abingworth founded?
Abingworth was founded in 1973.
-
Where is Abingworth headquartered?
Abingworth is headquartered in London, United Kingdom.
-
What is Abingworth's total asset value?
Abingworth has around in total assets under management.
-
How many investments has Abingworth made?
Abingworth has made 266 investments.
-
What has Abingworth invested in?
Abingworth has made numerous investments in companies like Glycomine, Atsena Therapeutics, and AdvanCell within the Drug Discovery industry.
-
What has Abingworth invested in recently?
Abingworth's latest investment was on 16-Apr-2025 in Glycomine, a company within the Drug Discovery industry.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
